About Verastem

Management Team

Robert Forrester, LL.B., President/Chief Executive Officer

Mr. Forrester has 14 years of experience as the CEO, COO or CFO of both private and public life science companies with Forma Therapeutics, CombinatoRx (NASDAQ: CRXX, now ZLCS) and Coley (NASDAQ: COLY, acquired by Pfizer). Robert was a managing director of the Proprietary Investment Group at MeesPierson, part of the Fortis Group, investing in life science companies. Prior to MeesPierson, Robert worked for the investment banks, BZW (now Barclays Capital) and UBS, in the corporate finance groups undertaking M&A, and public and private finance transactions. Robert started his career as lawyer with Clifford Chance in London and Singapore. Robert has completed over $12 billion of transactions and holds a LL.B. from Bristol University.

Top of Page

Gregory Berk, M.D., Chief Medical Officer

Dr. Berk comes to Verastem from Sideris Pharmaceuticals where he served as President, Chief Medical Officer, and a member of the Board of Directors since 2014. Prior to Sideris, Dr. Berk was Chief Medical Officer at BIND Therapeutics, Inc., where he led the clinical development of its oncology focused programs. Prior to BIND, he held senior clinical positions, including Chief Medical Officer, at a number of emerging biotechnology companies, including Intellikine LLC, and Abraxis Bioscience, Inc. for the development of Abraxane®. Dr. Berk is a board certified physician and obtained his medical degree from Case Western Reserve University, and completed his internship, residency, and fellowship in internal medicine, hematology, and medical oncology at the Weill Medical College of Cornell University and New York Presbyterian Hospital, where he also served as a faculty member from 1989–2004. During this time, Dr. Berk served as an investigator on several industry-sponsored and cooperative group clinical trials, including the pivotal trials for Gleevec® and Avastin®.

Top of Page

Jonathan Pachter, Ph.D., Chief Scientific Officer

Dr. Pachter brings over 25 years of experience in leading discovery and translational research for small molecule and monoclonal antibody anti-cancer therapeutics. He was previously Head of Cancer Biology at OSI Pharmaceuticals where his team was responsible for development of models of tumor cell EMT (epithelial-mesenchymal transition) and discovery of drugs disrupting this process. At OSI, he advanced five small molecules into development for treatment of cancer, including OSI-906 – a selective IGF-1R/ insulin receptor kinase inhibitor which progressed to Phase 3 clinical trials and OSI-027 – a selective mTOR kinase inhibitor. Prior to OSI, Dr. Pachter held positions of increasing responsibility at Schering-Plough where he progressed three agents into development including the monoclonal antibody robatumumab, which advanced to Phase 2 clinical evaluation in cancer patients. Dr. Pachter also made key contributions to the regulatory approval of temozolomide for treatment of glioblastoma. He is an author of over 50 peer-reviewed publications and inventor on numerous patents. Dr. Pachter did his postdoctoral work in Pharmacology at Yale University School of Medicine and he holds a Ph.D. from Baylor College of Medicine.

Top of Page

Dan Paterson, Chief Operating Officer

Mr. Paterson has over 25 years of experience in management roles at healthcare and biotechnology companies, including as CBO, COO and CEO, with specific expertise in oncology drug and diagnostic product development, business development and launch planning. Prior to his current role, he served as CBO of Verastem. Mr. Paterson was the Co-founder and COO of On-Q-ity, a developer of technology to capture and analyze circulating tumor cells, and the founding CEO of The DNA Repair Company (merged to form On-Q-ity), which developed oncology-focused molecular diagnostics. Prior to that, Mr. Paterson was Head of Global Strategy for Specialty Market and Patient-Level Data at IMS Health, after playing a key role in the acquisition of PharMetrics by IMS Health as VP, Marketing and Corporate Development. While at PharMetrics, Mr. Paterson led the development of an innovative suite of pharmaceutical product launch tools that became the basis of the company’s product line.

Earlier in his career, Mr. Paterson was on the founding management team of CareTools, a healthcare information systems company, OnCare, an oncology physician practice management company with $100 million in annual revenue, and Axion, an oncology pharmaceutical and clinical service firm with an annual revenue of over $250 million when acquired by Bristol Myers Squibb. Prior to his involvement in industry, Mr. Paterson led the clinical operations for a nationwide cancer cooperative group headquartered at the Dana Farber Cancer Institute. Mr. Paterson holds a B.A. in Biology from Boston University, and attended the Northeastern University Graduate Pharmacology program.

Top of Page

Steven Bloom, Senior Vice President, Corporate Development

Steven Bloom joined Verastem in March 2014 and serves as Senior Vice President of Corporate Development. His responsibilities include business development, commercial analysis and external relations. Prior to joining the company, Mr. Bloom was Senior Vice President at Ziopharm Oncology where for 6 years he led business development and the commercial planning initiatives for a late stage oncology asset. Before joining Ziopharm, Mr. Bloom was Senior Vice President for the health informatics company Pharmetrics and was part of the leadership team that sold the company to IMS Health in 2005. After leaving Eli Lilly in 2002, he joined the health technology company Inflexxion and built a commercial infrastructure for the start-up organization. Mr. Bloom spent the first 20 years of his career at Eli Lilly and Company in leadership roles in marketing, sales and corporate affairs.

Mr. Bloom is a graduate of The College of Pharmacy at Northeastern University and is currently an Adjunct Faculty member at the University of Rhode Island College of Pharmacy.

Top of Page